CAS 317318-70-0|GW501516
Introduction：Basic information about CAS 317318-70-0|GW501516, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | GW501516 | ||
|---|---|---|---|
| CAS Number | 317318-70-0 | Molecular Weight | 453.498 |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 584.5±60.0 °C at 760 mmHg |
| Molecular Formula | C21H18F3NO3S2 | Melting Point | 134-136°C |
| MSDS | ChineseUSA | Flash Point | 307.3±32.9 °C |
Names
| Name | 2-[2-methyl-4-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]phenoxy]acetic acid |
|---|---|
| Synonym | More Synonyms |
GW501516 BiologicalActivity
| Description | GW 501516 is a PPARδ agonist with an EC50 of 1.1 nM. |
|---|---|
| Related Catalog | Signaling Pathways >>Autophagy >>AutophagySignaling Pathways >>Cell Cycle/DNA Damage >>PPARResearch Areas >>Metabolic Disease |
| Target | PPARδ:1.1 nM (EC50) |
| In Vitro | GW 501516 is shown to be the most potent and selective PPARα agonists known with an EC50 of 1.1 nM against PPARα and 1000-fold selectivity over the other human subtypes, PPARα and-γ[1]. GW 501516 exerts anti-inflammatory effects in mouse cultured proximal tubular (mProx) cells. GW 501516 inhibits palmitate- and TNFα-induced increases in MCP-1 mRNA expression in a dose-dependent manner[3]. |
| In Vivo | GW 501516 causes impaired bone formation, leading to decreased BMD and deterioration of bone properties in OVX rats[2]. GW 501516 attenuates interstitial inflammation and proximal tubular cell damage in a protein-overload mouse nephropathy model[3]. GW 501516 treatment enhances running endurance and the proportion of succinate dehydrogenase (SDH)-positive muscle fibres in both trained and untrained mice[4]. |
| Cell Assay | GW 501516 is dissolved in DMSO. Cells are starved by incubation in 0.2% FCS DMEM for 9 h, then pre-incubated with GW 501516, at a final concentration of 2.5 and 5 µM, or 0.05% DMSO as control for 3 hours, followed by stimulation with 150 µM palmitate bound to 8.0% BSA for 12 h[3]. |
| Animal Admin | Rats: Female Sprague Dawley rats, 12 weeks of age, are allocated to a sham-operated group and 3 OVX groups; high-dose GW 501516 (OVX-GW5), low-dose GW 501516 (OVX-GW1), and a control group (OVX-CTR), respectively. Animals receive GW 501516 or vehicle (methylcellulose) daily for 4 months by gavage. Bone mineral density (BMD) is assessed by dual x-ray absorptiometry at the femur, spine, and whole body[2]. Mice: Mice are randomly allocated to different groups and receive therapeutic diet and treatment. The GW 501516-containing rodent diet is made by evenly adding GW 501516 to the control diet to a final concentration of 0.04% w/w. In the control diet, 10% of the total calories are from fat (5.5% from soybean oil and 4.5% from lard)[3]. |
| References | [1]. Wei ZL, et al. A short and efficient synthesis of the pharmacological research tool GW501516 for the peroxisome proliferator-activated receptor delta. J Org Chem. 2003 Nov 14;68(23):9116-8. [2]. Mosti MP, et al. Effects of the peroxisome proliferator-activated receptor (PPAR)-δ agonist GW 501516 on bone and muscle in ovariectomized rats. Endocrinology. 2014 Jun;155(6):2178-89. [3]. Yang X, et al. GW 501516, a PPARδ agonist, ameliorates tubulointerstitial inflammation in proteinuric kidney disease via inhibition of TAK1-NFκB pathway in mice. PLoS One. 2011;6(9):e25271. [4]. Chen W, et al. A metabolomic study of the PPARδ agonist GW 501516 for enhancing running endurance in Kunming mice. Sci Rep. 2015 May 6;5:9884. [5]. Ji Y, et al. PPARβ/δ Agonist GW501516 Inhibits Tumorigenicity of Undifferentiated Nasopharyngeal Carcinoma in C666-1 Cells by Promoting Apoptosis. Front Pharmacol. 2018 Jun 28;9:648. |
Chemical & Physical Properties
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 584.5±60.0 °C at 760 mmHg |
| Melting Point | 134-136°C |
| Molecular Formula | C21H18F3NO3S2 |
| Molecular Weight | 453.498 |
| Flash Point | 307.3±32.9 °C |
| Exact Mass | 453.068024 |
| PSA | 112.96000 |
| LogP | 6.29 |
| Vapour Pressure | 0.0±1.7 mmHg at 25°C |
| Index of Refraction | 1.619 |
| InChIKey | YDBLKRPLXZNVNB-UHFFFAOYSA-N |
| SMILES | Cc1cc(SCc2sc(-c3ccc(C(F)(F)F)cc3)nc2C)ccc1OCC(=O)O |
| Storage condition | Refrigerator |
| Stability | Light Sensitive |
| Water Solubility | DMSO: soluble20mg/mL, clear |
Safety Information
| Hazard Codes | Xi |
|---|---|
| RIDADR | NONH for all modes of transport |
| RTECS | AI9105500 |
Synonyms
| GW 501516 |
| Acetic acid, 2-[2-methyl-4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]thio]phenoxy]- |
| 2-(4-((2-(4-(Trifluoromethyl)phenyl)-5-methylthiazol-4-yl)methylthio)-2-methylphenoxy)acetic acid |
| 2-(2-BROMOPHENYL)-3'-TRIFLUOROMETHYLACETOPHENONE |
| 2-methyl-4-(((4-methyl-2-(4-(trifluoromethyl)phenyl)-5-(thiazolyl)methyl)thio)phenoxy)acetic acid |
| Endurobol |
| {2-Methyl-4-{{4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl}methylthio}phenoxy}acetic acid |
| UNII-7I2HA1NU22 |
| GSK-516 |
| Cardarine |
| GW-501516 |
| GW501516 |
